Catheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy

Rhea-AI Summary

Catheter Precision (NYSE American: VTAK) received a Notice of Allowance from the USPTO on April 21, 2026, for key claims covering its LockeT surgical vessel closing pressure device.

The allowed claims protect both the device architecture and method of use, reinforcing the company’s intellectual property position, creating barriers to entry, and supporting its IP-driven commercialization and growth strategy.

Positive

• USPTO Notice of Allowance received on April 21, 2026
• Claims cover both device architecture and method of use
• Stronger barriers to entry from comprehensive IP protection
• Supports commercialization and long-term IP-driven growth strategy

Negative

• None.

News Market Reaction – VTAK

-2.56%

3 alerts

-2.56% News Effect

+24.9% Peak Tracked

-$69K Valuation Impact

$2.63M Market Cap

0.0x Rel. Volume

On the day this news was published, VTAK declined 2.56%, reflecting a moderate negative market reaction. Argus tracked a peak move of +24.9% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $69K from the company's valuation, bringing the market cap to $2.63M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Revenue growth: 95% year over year GAAP net loss: $17.7M Non-GAAP net loss: $7.8M +5 more

8 metrics

Revenue growth 95% year over year Full-year 2025 results

GAAP net loss $17.7M Full-year 2025

Non-GAAP net loss $7.8M Full-year 2025 adjusted

GAAP net loss $5.3M Q4 2025

Non-GAAP net loss $3.5M Q4 2025 adjusted

Capital raised $4.9M Capital raised during 2025

Shares outstanding 2,692,473 shares As of March 20, 2026 (10-K)

Series C conversion capacity 252,047,623 shares Potential common from Series C preferred (proxy)

Market Reality Check

Price: $0.8856 Vol: Volume 177,211 vs 20-day ...

normal vol

$0.8856 Last Close

Volume Volume 177,211 vs 20-day average 217,448, indicating relative volume of 0.81x into this news. normal

Technical Shares at $0.975 are trading below the 200-day MA of $2.32 and sit far under the 52-week high of $15.6805.

Peers on Argus

VTAK is up 10.78% while momentum-flagged peers TIVC and BJDX are both down (sect...

2 Down

VTAK is up 10.78% while momentum-flagged peers TIVC and BJDX are both down (sector scanner median about -4.1%), pointing to stock-specific strength rather than a sector-wide move.

Historical Context

5 past events · Latest: Apr 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Apr 20	Aviation expansion	Positive	+10.8%	Flyte expansion to capture demand from airline route cuts and fuel-driven retrenchment.
Apr 16	Flyte acquisition	Positive	-13.2%	Shareholder-approved acquisition of Fly Flyte, adding a revenue-generating aviation platform.
Apr 13	VIVO study publication	Positive	+2.5%	EP Europace acceptance of VIVO VT mapping study with high specificity in NICM patients.
Apr 08	Conference presence	Positive	-1.7%	Plans to showcase LockeT and new data at the EHRA conference in Paris.
Apr 06	LockeT clinical data	Positive	+2.1%	Journal acceptance of LockeT data in 139 patients showing high success and low complications.

Pattern Detected

Recent company-specific news has produced mixed reactions, with both sharp rallies and drawdowns around strategic updates.

Recent Company History

Over the past weeks, VTAK has combined medical device progress with a diversification into regional air services. On April 6, 2026, LockeT data in 139 patients supported its venous closure strategy, followed by European conference visibility and a VIVO publication in EP Europace. The company then closed the Flyte acquisition and highlighted Flyte’s role in capturing displaced short‑haul demand on April 20, 2026. Today’s LockeT patent allowance further reinforces the cardiac platform’s IP, adding to the broader pivot that now spans medical devices and aviation.

Market Pulse Summary

This announcement adds a USPTO Notice of Allowance on LockeT’s vessel closure technology, strengthen...

Analysis

This announcement adds a USPTO Notice of Allowance on LockeT’s vessel closure technology, strengthening Catheter Precision’s IP position around a core cardiac platform. Recent history includes encouraging LockeT and VIVO data, European conference exposure, and diversification via the Flyte acquisition. At the same time, SEC filings report a $17.7M 2025 GAAP net loss, going‑concern uncertainty, and substantial potential dilution from preferred structures. Investors may watch commercialization progress, funding transactions, and execution across both medical and aviation segments.

Key Terms

notice of allowance, hemostasis, ce mark, gaap, +4 more

8 terms

notice of allowance regulatory

"the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance"

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

hemostasis medical

"pressure application after vascular procedures, supporting effective hemostasis."

Hemostasis is the body’s process for stopping bleeding, using a coordinated set of responses that form clots and seal damaged vessels—think of it as the body's natural emergency patch and repair crew. It matters to investors because drugs, medical devices, and diagnostics that influence hemostasis can affect patient outcomes, regulatory approval paths, and market demand for treatments of bleeding disorders or clot-related conditions, so advances or safety issues can materially impact company value.

ce mark regulatory

"educate physicians and distributors about LockeT after CE Mark receipt."

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

gaap financial

"revenue growth of 95% year over year but a GAAP net loss of $17.7M."

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

non-gaap financial

"reported a 2025 non-GAAP adjusted net loss of $7.8M."

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

reverse stock split financial

"authorize a reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑100"

A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.

convertible preferred stock financial

"issue Series C, Series D, Series J and reduced‑price Series B convertible preferred stock"

Convertible preferred stock is a special class of company shares that pays priority, usually fixed, payments to holders and can be exchanged later for a set number of common shares. It matters to investors because it combines steady income and added protection with the chance to share in a company’s upside; think of it as a hybrid between a bond that pays regularly and an option to convert into growth-oriented stock, where the conversion rules influence both potential gains and how much common shareholders’ ownership may be reduced.

going concern financial

"reports a going concern uncertainty, highlighting an accumulated deficit"

A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.

AI-generated analysis. Not financial advice.

USPTO Validates Catheter Precision’s LockeT Technology with Key Patent Allowance, Reinforcing Competitive Dominance, Long-Term Value Creation and Strengthening Barriers to Entry

FORT MILL, S.C., April 21, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for key claims covering its proprietary surgical vessel closing pressure device, marking a significant milestone in the Company’s intellectual property strategy.

Following a rigorous examination process, the USPTO confirmed the novelty and patentability of VTAK’s technology over existing prior art. The allowed claims provide protection across both the core device architecture and its method of use, creating a comprehensive and defensible intellectual property position around a foundational component of the Company’s platform.

The patented system incorporates a differentiated design enabling precise control of suture tension and pressure application after vascular procedures, supporting effective hemostasis. By securing protection over both structural and functional elements of the technology, VTAK is establishing meaningful barriers to entry and reinforcing its competitive position in complex procedural markets.

“This milestone further underscores Catheter Precision’s commitment to innovation and strengthens its foundation for driving significant long-term shareholder value,” said David A. Jenkins, Chief Executive Officer of Catheter Precision. He continued, “VTAK continues to execute on its strategy of developing differentiated, high-impact medical technologies supported by strong intellectual property protection, positioning the Company for sustained growth and long-term value creation.”

This milestone represents a critical step in building a scalable, IP-driven medical technology platform. The Company believes its expanding patent portfolio will play a key role in supporting long-term commercialization, product development, and potential strategic opportunities.

About LockeT

Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision

Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements.

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

FAQ

What did Catheter Precision (VTAK) announce on April 21, 2026 regarding patents?

They received a Notice of Allowance from the USPTO for key claims on their LockeT vessel closing device. According to the company, the allowance covers both the device architecture and the method of use, strengthening its intellectual property position.

How does the USPTO allowance affect Catheter Precision’s (VTAK) competitive position?

The allowance strengthens competitive barriers by protecting design and use of the device. According to the company, the allowed claims create a comprehensive, defensible IP position that reinforces market differentiation and entry barriers.

Which aspects of the LockeT technology are protected by the new VTAK patent allowance?

The allowed claims protect both the core device architecture and the method of use. According to the company, protection spans structural and functional elements, including precise suture tension and pressure control for hemostasis.

Will the patent allowance support Catheter Precision’s (VTAK) commercialization plans?

The company says the allowance will support long-term commercialization and product development. According to the company, the expanding patent portfolio is expected to play a key role in supporting scalable, IP-driven opportunities.

Does the USPTO notice mean LockeT is cleared for clinical use or sale by VTAK?

No, a patent allowance protects intellectual property but is not a regulatory clearance for clinical use or sale. According to the company, the allowance secures IP; separate regulatory approvals are required for market commercialization.

How might VTAK’s patent allowance influence investor perception of Catheter Precision?

The allowance may be viewed as validation of innovation and stronger IP protection. According to the company, it underscores commitment to differentiated medical technologies and is positioned as a step toward long-term shareholder value creation.